Chlordiazepoxide
Benzodiazepine — NERVOUS SYSTEM
Also known as: chlordiazepoxid, chlordiazepoxide HCl, chlordiazepoxide hydrochloride, chloridazepoxide, chlorodiazepoxide, methaminodiazepoxide
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Chlordiazepoxide is an ofp drug in the Benzodiazepine class catalogued in DrugCentral. It was first approved by the FDA in 1960. DrugCentral lists 16 molecular targets, including Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre, HRH1 and GABRG2|GABRB3|GABRA3. Recorded indications include Alcohol withdrawal delirium, Alcohol withdrawal syndrome, Anxiety and Anxiety associated with Menopause.
- Approval status: ofp (first approved 1960 by the FDA).
- Drug class: Benzodiazepine.
- Molecular targets: Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre, HRH1, GABRG2|GABRB3|GABRA3 and TRHR (16 listed in DrugCentral).
- Indications: Alcohol withdrawal delirium, Alcohol withdrawal syndrome, Anxiety, Anxiety associated with Menopause and General anesthesia and others.
- ATC code: N05BA02 (Benzodiazepine derivatives).
- Molecular formula: C16H14ClN3O; molecular weight 299.76 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (12)
- Alcohol withdrawal delirium
- Alcohol withdrawal syndrome
- Anxiety
- Anxiety associated with Menopause
- General anesthesia
- Irritable bowel syndrome
- Local anesthesia
- Mixed anxiety and depressive disorder
- Peptic ulcer
- Pre-Op Apprehension
- Preoperative Anxiety
- Severe anxiety (panic)
Off-label uses (1)
- Panic disorder
Contraindications (87)
- Achalasia of esophagus
- Alcohol intoxication
- Alcoholism
- Angle-closure glaucoma
- Asthma
- Atony of colon
- Autonomic dysreflexia
- Benign prostatic hyperplasia
- Bipolar affective disorder, current episode manic
- Bladder outflow obstruction
- Bleeding
- Body fluid retention
- Brain damage
- Breast lump
- Breastfeeding (mother)
- Carcinoma of female breast
- Cardiovascular event risk
- Cerebrovascular accident
- Chloasma
- Chorea
- Chronic heart failure
- Chronic idiopathic constipation
- Chronic lung disease
- Complete trisomy 21 syndrome
- Conduction disorder of the heart
- Congenital long QT syndrome
- Deep venous thrombosis
- Dementia
- Depressive disorder
- Diabetes mellitus
- + 57 more
Mechanism & targets
| Established pharmacologic class | Benzodiazepine |
|---|
Molecular targets (16)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA-A receptor; anion channel | Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre | unknown | IC50 6.70 |
| Histamine H1 receptor | HRH1 | unknown | Ki 6.68 |
| GABA-A receptor alpha-3/beta-3/gamma-2 | GABRG2|GABRB3|GABRA3 | positive allosteric modulator | Ki 6.56 |
| Thyrotropin-releasing hormone receptor | TRHR | unknown | Ki 6.54 |
| Cholinesterase | BCHE | unknown | Ki 6.52 |
| GABA-A receptor alpha-5/beta-3/gamma-2 | GABRG2|GABRB3|GABRA5 | positive allosteric modulator | Ki 6.50 |
| Translocator protein | Tspo | unknown | Ki 6.36 |
| GABA-A receptor alpha-2/beta-3/gamma-2 | GABRG2|GABRB3|GABRA2 | positive allosteric modulator | Ki 6.34 |
| GABA-A receptor alpha-1/beta-2/gamma-2 | GABRA1|GABRG2|GABRB2 | positive allosteric modulator | Ki 6.25 |
| GABA-A receptor alpha-1/beta-3/gamma-2 | GABRA1|GABRG2|GABRB3 | unknown | Ki 6.25 |
| GABA-A receptor; anion channel | GABRA1|GABRB1|GABRA2|GABRA3|GABRA4|GABRG2 | unknown | IC50 6.10 |
| Thyrotropin-releasing hormone receptor | Trhr | antagonist | Ki 4.82 |
| Thyrotropin-releasing hormone receptor | Trhr | antagonist | Ki 4.70 |
| Acetylcholinesterase | ache | unknown | Ki 4.30 |
| Cholecystokinin receptor | Cckar|Cckbr | unknown | IC50 4.00 |
| Cholecystokinin receptor | CCKAR|CCKBR | unknown | IC50 4.00 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1960-02-24 | FDA | — | VALEANT PHARM INTL |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N05BA02 | NERVOUS SYSTEM › PSYCHOLEPTICS › ANXIOLYTICS › Benzodiazepine derivatives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug abuse | 409.6 |
| Toxicity to various agents | 303.8 |
| Cerebral venous thrombosis | 219.7 |
| Completed suicide | 132.8 |
| Drug interaction | 129.1 |
| Ventricular tachyarrhythmia | 98.8 |
| Overdose | 95.4 |
| Dystonic tremor | 94.0 |
| Bradyphrenia | 90.9 |
| Hyperreflexia | 81.0 |
| Delirium | 80.3 |
| Sopor | 80.3 |
Chemical structure
| Molecular formula | C16H14ClN3O |
|---|---|
| Molecular weight | 299.76 g/mol |
| CAS number | — |
| InChIKey | ANTSCNMPPGJYLG-UHFFFAOYSA-N |
| PubChem CID | 2712 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Chlordiazepoxide used for?
DrugCentral lists the following indications for Chlordiazepoxide: Alcohol withdrawal delirium, Alcohol withdrawal syndrome, Anxiety, Anxiety associated with Menopause, General anesthesia, Irritable bowel syndrome, Local anesthesia and Mixed anxiety and depressive disorder and others.
How does Chlordiazepoxide work?
Its molecular targets in DrugCentral include Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre, HRH1, GABRG2|GABRB3|GABRA3 (positive allosteric modulator) and TRHR.
When was Chlordiazepoxide first approved?
Chlordiazepoxide was first approved by the FDA in 1960.
What drug class does Chlordiazepoxide belong to?
Chlordiazepoxide is in the Benzodiazepine class.
What is the chemical formula of Chlordiazepoxide?
Chlordiazepoxide has the molecular formula C16H14ClN3O and a molecular weight of 299.76 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 594 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200703 — compound record and bioactivity
- PubChem CID 2712 — chemical identifiers
- DrugBank DB00475 — drug record
- FDA UNII 6RZ6XEZ3CR — substance identity
- DailyMed: FDA labels for Chlordiazepoxide — current prescribing information (label search)
- UniProt P35367 (HRH1) — target protein
- UniProt P34981 (TRHR) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.